logo-loader
Zelda Therapeutics Ltd

Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute

The ICCI provides access to a global network of specialist services.

collaboration concept
The engagement with ICCI brings together a world-leading medical advisory team

Zelda Therapeutics Ltd (ASX:ZLD) has engaged the International Cannabis and Cannabinoids Institute (ICCI) to support its clinical trial programs in autism, opioid reduction and insomnia. 

This provides Zelda with an opportunity to collaborate with a panel of leading international medicinal cannabis experts.

The ICCI is an international centre of excellence for the advancement of cannabis and cannabinoid treatments.

The ICCI provides access to a global network of specialist services including expert advice on clinical study design and execution, requirements for regulatory approval, a full range of contract research services and direct liaison with study investigators.

READ: Zelda Therapeutics on track to report on multiple clinical trials

Zelda’s managing director Dr Richard Hopkins said: “We’re honoured to be working with the ICCI and Dr Ethan Russo, who are recognised globally as leading authorities on medicinal cannabis. Their insights will help inform and accelerate our clinical trial programs.

“Dr Russo and the ICCI will complement our existing medical advisory team and maintains Zelda’s strategy of engaging the world’s best medicinal cannabis researchers and clinicians.”

Dr Ethan Russo was recently appointed the Director of Research and Development at the ICCI.

He is a US-trained board-certified paediatric and adult neurologist, psychopharmacology researcher, former Senior Medical Advisor to GW Pharmaceuticals, and Medical Director of PHYTECS.

Dr Russo said: “I’m delighted to be collaborating with Zelda who is at the forefront of efforts to develop plant-derived cannabis medicines that have the potential to improve quality of life for patients.”

Progressing clinical and pre-clinical activities in 2019

Zelda remains on-track to report on the outcome from its clinical trials for insomnia, autism and opioid reduction by mid-2019.

The company is also continuing to assess opportunities to expand its clinical programs where they align with its strategic objectives.

Finally, Zelda is progressing discussions with third parties aiming at securing agreements to distribute clinically-validated Zelda products globally.

Quick facts: Zelda Therapeutics Ltd

Price: $0.07

Market: ASX
Market Cap: $49.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelda Therapeutics Ltd named herein, including the promotion by the Company of Zelda Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in...

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC. The deal complements a number of...

on 12/3/19

2 min read